

Request under Freedom of Information Act 2000

Request Ref: NGFOI 18/19: 103

Thank you for your request for information received at Northampton General Hospital NHS Trust (NGH) on 14/05/2018.

I am pleased to be able to provide you with the following information:

For period 01.11.17 – 30.04.18

- In your trust how many patients with Multiple Sclerosis have been treated with MS disease modifying drugs in the past 6 months, latest 6 months that you can provide? 182
- 2. Please provide the number of patients by treatment for the following disease modifying drugs.

•	Aubagio (teriflunomide)	20
•		
•	Avonex (interferon beta-1a)	8
•	Betaferon (interferon beta-1b)	1
•	Copaxone (glatiramer acetate)	36
•	Glatiramer acetate generic [eg Brabio]	0
•	Extavia (beta interferon-1b)	1
•	Gilenya (fingolimod)	9
•	Lemtrada (alemtuzumab)	10
•	Rebif (beta interferon-1a)	27
•	Tecfidera (dimethyl fumarate)	45
•	Tysabri (natalizumab)	17
•	Ampyra (Fampyra)	0
•	Peginterferon beta-1a (Plegridy)	8
•	Daclizumab (Zinbryta)	0
•	Cladribine (Mavenclad)	0
•	Others	0